Fill Out Your Profile to share more about you. Learn more...

FDA Approves Enhertu for Unresectable or Metastatic HER2-Low BC

Options

FDA Approves Enhertu for Unresectable or Metastatic HER2-Low Breast Cancer
Aug 5, 2022

On Aug. 5, 2022, the U.S. Food and Drug Administration approved Enhertu to treat unresectable or metastatic HER2-low breast cancer. Read more...